论文部分内容阅读
目的探讨急性髓系白血病染色体核型与化疗疗效关系。方法对本院自2010年8月至2012年8月收治的58例急性髓系白血病患者临床资料进行回顾性分析,采用G显带常规技术分析其染色体核型。结果异常核型21例(36.2%),非M3患者均按照MRC标准将预后分为优良、中、差3组,给予患者CAG或者TA方案化疗,M3患者缓解率明显优于非M3患者,P<0.05;TA方案治疗中优良及中等组患者缓解率明显优于差组,P<0.05;CAG方案下,中等组缓解率明显高于优良组及差组,P<0.05,优良组与差组差异无统计学意义,P>0.05。结论对急性髓系白血病染色体核型分析,有助于较好指导预后判断及化疗效果,CAG治疗初始、原发老年白血病或者增生性急性髓系白血病患者有显著的临床价值。
Objective To investigate the relationship between the chromosomal karyotype of acute myeloid leukemia and chemotherapy. Methods The clinical data of 58 patients with acute myeloid leukemia treated in our hospital from August 2010 to August 2012 were analyzed retrospectively. The karyotypes of the patients were analyzed by G - banding routine technique. Results The abnormal karyotypes were found in 21 cases (36.2%). The non-M3 patients were divided into three groups according to the MRC criteria. The prognosis was divided into three groups according to MRC criteria: CAG or TA regimen. The response rate was significantly higher in M3 patients than in non-M3 patients <0.05; remission rate of the patients in the superior and middle groups of TA regimen was significantly better than that of the poor group (P <0.05). Under the CAG regimen, the remission rate of the middle regimen was significantly higher than that of the good and bad groups, P <0.05, The difference was not statistically significant, P> 0.05. Conclusion Chromosome karyotype analysis of acute myeloid leukemia can be helpful to predict the prognosis and chemotherapeutic effect. It has significant clinical value in patients with initial CAG, primary AML or proliferative Acute Myeloid Leukemia.